The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium
Open accessAbstract
Here we report a genetically modified bacteria strain, Salmonella typhimurium A1, selected for anticancer activity in vivo . The strain grows in tumor xenografts. In sharp contrast, normal tissue is cleared of these bacteria even in immunodeficient athymic mice. S . typhimurium A1 is auxotrophic (Leu/Arg-dependent) but apparently receives sufficient support from the neoplastic tissue to grow locally. Whether additional genetic lesions are present is not known. In in vitro infection, the GFP-expressing bacteria grew in the cytoplasm of PC-3 human prostate cancer cells and caused nuclear destruction. These effects were visualized in cells labeled with GFP in the nucleus and red fluorescent protein in the cytoplasm. In vivo , the bacteria caused tumor inhibition and regression of xenografts visualized by whole-body imaging. The bacteria, introduced i.v. or intratumorally, invaded and replicated intracellularly in PC-3 prostate cancer cells labeled with red fluorescent protein grafted into nude mice. By day 15, S . typhimurium A1 was undetectable in the liver, lung, spleen, and kidney, but it continued to proliferate in the PC-3 tumor, which stopped growing. When the bacteria were injected intratumorally, the tumor completely regressed by day 20. There were no obvious adverse effects on the host when the bacteria were injected by either route. The S . typhimurium A1 strain grew throughout the tumor, including viable malignant tissue. This result is in marked contrast to bacteria previously tried for cancer therapy that were confined to necrotic areas of the tumor, which may account, in part, for the strain's unique antitumor efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines
Hoiseth, S. K., & Stocker, B. A. D. (1981) · Nature · doi:10.1038/291238a0 · Cited by 2,078
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,748
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
Self-citationToso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614
Combination bacteriolytic therapy for the treatment of experimental tumors
Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., & Vogelstein, B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251543698 · Cited by 563
Tumor-targeted Salmonella as a novel anticancer vector.
Pawelek, J. M., Low, K. B., & Bermudes, D. G. (1997) · PubMed · Cited by 527
Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases
Yang, M., Baranov, E., Jiang, P., Sun, F.-X., Li, X.-M., Li, L., Hasegawa, S., Bouvet, M., Al-Tuwaijri, M., Chishima, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.3.1206 · Cited by 514
Self-citationDissecting p53 tumor suppressor functions in vivo
Schmitt, C. A., Fridman, J. S., Yang, M., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00047-8 · Cited by 485
Self-citationLow, K. B., Ittensohn, M., Le, T., Platt, J., Sodi, S., Amoss, M., Ash, O., Carmichael, E., Chakraborty, A., Fischer, J., et al. (1999) · Nature Biotechnology · doi:10.1038/5205 · Cited by 476
Yu, Y. A., Shabahang, S., Timiryasova, T. M., Zhang, Q., Beltz, R., Gentschev, I., Goebel, W., & Szalay, A. A. (2004) · Nature Biotechnology · doi:10.1038/nbt937 · Cited by 423
Cited by
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Fang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9537 · Cited by 588
Environmentally Controlled Invasion of Cancer Cells by Engineered Bacteria
Anderson, J. C., Clarke, E. J., Arkin, A. P., & Voigt, C. A. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.10.076 · Cited by 572
Bacteria-cancer interactions: bacteria-based cancer therapy
Duong, M. T.-Q., Qin, Y., You, S.-H., & Min, J.-J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0297-0 · Cited by 519
Programmable probiotics for detection of cancer in urine
Danino, T., Prindle, A., Kwong, G. A., Skalak, M., Li, H., Allen, K., Hasty, J., & Bhatia, S. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3519 · Cited by 467
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Leventhal, D. S., Sokolovska, A., Li, N., Plescia, C., Kolodziej, S. A., Gallant, C. W., Christmas, R., Gao, J.-R., James, M. J., Abin-Fuentes, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16602-0 · Cited by 458
Mobile microrobots for bioengineering applications
Ceylan, H., Giltinan, J., Kozielski, K., & Sitti, M. (2017) · Lab on a Chip · doi:10.1039/c7lc00064b · Cited by 392
Bioengineered and biohybrid bacteria-based systems for drug delivery
Hosseinidoust, Z., Mostaghaci, B., Yasa, O., Park, B.-W., Singh, A. V., & Sitti, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.09.007 · Cited by 368
Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities
Sedighi, M., Zahedi Bialvaei, A., Hamblin, M. R., Ohadi, E., Asadi, A., Halajzadeh, M., Lohrasbi, V., Mohammadzadeh, N., Amiriani, T., Krutova, M., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2148 · Cited by 308
Zhao, M., Yang, M., Ma, H., Li, X., Tan, X., Li, S., Yang, Z., & Hoffman, R. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0716 · Cited by 305
Self-citationNanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
MAEDA, H. (2012) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.88.53 · Cited by 291
Short hairpin RNA–expressing bacteria elicit RNA interference in mammals
Xiang, S., Fruehauf, J., & Li, C. J. (2006) · Nature Biotechnology · doi:10.1038/nbt1211 · Cited by 271
A programmable encapsulation system improves delivery of therapeutic bacteria in mice
Harimoto, T., Hahn, J., Chen, Y.-Y., Im, J., Zhang, J., Hou, N., Li, F., Coker, C., Gray, K., Harr, N., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01244-y · Cited by 260
Gut microbiota, inflammation and colorectal cancer
Sun, J., & Kato, I. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.03.004 · Cited by 257
“In animal models, Salmonella and its derivatives have been observed invading transformed tissue more efficiently than normal tissue.(141,142) Salmonella AvrA is a multifunctional protein that influences eukaryotic cell pathways by altering ubiquitination and acetylation of target proteins.”
BackgroundStritzker, J., Weibel, S., Hill, P. J., Oelschlaeger, T. A., Goebel, W., & Szalay, A. A. (2007) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.01.008 · Cited by 224
Lu, R., Wu, S., Zhang, Y.-G., Xia, Y., Liu, X., Zheng, Y., Chen, H., Schaefer, K. L., Zhou, Z., Bissonnette, M., et al. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.20 · Cited by 206
Bacteria as vectors for gene therapy of cancer
Baban, C. K., Cronin, M., O’Hanlon, D., O’Sullivan, G. C., & Tangney, M. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.6.13146 · Cited by 175
Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions
Kramer, M. G., Masner, M., Ferreira, F. A., & Hoffman, R. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00016 · Cited by 145
Self-citationSalmonella protein AvrA activates the STAT3 signaling pathway in colon cancer
Lu, R., Wu, S., Zhang, Y.-G., Xia, Y., Zhou, Z., Kato, I., Dong, H., Bissonnette, M., & Sun, J. (2016) · Neoplasia · doi:10.1016/j.neo.2016.04.001 · Cited by 99
Tumor vascular infarction: prospects and challenges
Jahanban-Esfahlan, R., Seidi, K., & Zarghami, N. (2017) · International Journal of Hematology · doi:10.1007/s12185-016-2171-3 · Cited by 88
ECM-targeting bacteria enhance chemotherapeutic drug efficacy by lowering IFP in tumor mouse models
Kim, J.-S., Park, J.-E., Choi, S.-H., Kang, S. W., Lee, J. H., Lee, J.-S., Shin, M., & Park, S.-H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.001 · Cited by 61
Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation
Seidi, K., Jahanban-Esfahlan, R., & Zarghami, N. (2017) · Tumor Biology · doi:10.1177/1010428317691001 · Cited by 41
Zahedifard, Z., Mahmoodi, S., & Ghasemian, A. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2738 · Cited by 12
Metadata
- Authors
- Zhao, M., Yang, M., Li, X.-M., Jiang, P., Baranov, E., Li, S., Xu, M., Penman, S., & Hoffman, R. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-01-11
- Volume
- 102
- Issue
- 3
- Pages
- 755-760
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2082013458
- Cited by
- 484
- References
- 29
- FWCI
- 13.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.